Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07265986

Comparison Between a Robotic Tele-echo-cardiography Technique and a Standard Echocardiography in the Management of Heart Failure in the Guadeloupe Archipelago Between the University Hospital of Guadeloupe and the Marie-Galante Hospital

The TERdeblue-S study is a feasibility study of robotic remote echocardiography, not only in terms of technology but also in terms of its integration into a telemedicine system to improve access to the heart failure management system in the Guadeloupe archipelago. The main objective of this study is to study the agreement of the measurement of the left ventricular ejection fraction (FejVG) between in situ echocardiography (EIS) and two-dimensional remote echocardiography (TER) (distance and volumes).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier Sainte-Marie de Marie-Galante, Grand-Bourg, Guadeloupe

Loading trial locations.

About this study

Considered as the new global epidemic of the 21st century, heart failure (HF) is a major public health issue. In 2010, the Guadeloupe region already had the highest rate of heart failure deaths in all French departments, furthermore cardiac decompensation of chronic heart failure is the first cardiovascular pathology to be managed in emergency medicine and the first cardiovascular cause of hospitalization. Marie-Galante is an island in the Guadeloupe archipelago, 36% of whose hospital stays are covered by the University Hospital Currently, access to specialized care in Marie-Galante, particularly cardiological care, is very limited with one to two monthly consultations by a specialist cardiologist accessible to a population . Rather, remote echocardiography has been the subject of experimental studies but has not yet been proposed as part of an optimization of the management of a specific cardiovascular disease at separate sites. This is a prospective multicentre study (two cardiologists in private practice of Guadeloupe and one at the Marie-Galante Hospital) interventional cross-over study in which the left ventricular ejection fraction (LVEF) will be the main judgement criterion. Patients will be randomized to determine the order of implementation of the techniques (echocardiography and then teleecardiography or the reverse). In addition, in order to take into account the operator effect, each of the 2 cardiologists will move alternately either for remote echocardiography or to Marie-Galante for in situ echocardiography.

The visit (V1) takes place at Marie-Galante's CH, as soon as possible after inclusion by the generalist practicionner or the cardiologist (V0) and is carried out by the state-registered nurse with a blood sample (biological check-up and biological collection) and ECG Holter place over 24 hours.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Free, informed and written consent signed by the participant and the investigator
  • Person affiliated or benefiting from a social security scheme.
  • Patient meeting at least one of the following criteria:
  • Systematic cardiovascular check-up or asymptomatic patient with cardiovascular risk factor (hypertension, diabetes, obesity, tobacco, alcohol)
  • Clinical suspicion of heart disease and/or chronic heart failure with stability of at least one week.
  • Family history of heart disease and/or sudden death

Exclusion criteria

  • Patient requiring urgent cardiological management with transfer to the University Hospital
  • Acute unstable heart failure, admission to CH Marie-Galante less than 5 days (less than one week)
  • Pregnant women

Treatment and study plan

in situ echocardiography (EIS)

Diagnostic Test

In situ echocardiography (EIS) will be performed by the cardiologist present in Marie-Galante Hospital.

two-dimensional remote echocardiography (TER)

Diagnostic Test

Remote echocardiography is performed by a cardiologist from a private practice in Guadeloupe, with a research nurse present at the patient's side at Marie-Galante Hospital.

Primary outcomes

  1. Agreement of Left Ventricular Ejection Fraction (LVEF) Measurements Between Echocardiography Techniques

    Time frame: Measured at the second visit (V2) at 2 weeks.

    The main outcome measure is the agreement of left ventricular ejection fraction (LVEF) measurements between two echocardiography techniques. Agreement will be quantified using the intraclass correlation coefficient (ICC) and supplemented by Bland-Altman plots to visualize differences between methods.

Secondary outcomes

  1. Agreement Between Echocardiography Techniques for Diagnosis of Cardiac Anomalies

    Time frame: Measured at the second visit (V2) at 2 weeks.

    Agreement between two echocardiography techniques for diagnosing cardiac anomalies (dilated cardiomyopathy, hypertrophic cardiomyopathy, and valvulopathies) will be evaluated using the Kappa coefficient. Sensitivity and specificity of each technique for each anomaly will also be reported.

  2. Dilated Cardiomyopathy Assessment

    Time frame: Measured at Visit 2 (V2), 2 weeks after baseline.

    Presence or absence of dilated cardiomyopathy will be defined according to left ventricular telediastolic diameter and reported as number of participants with dilated cardiomyopathy for each technique.

  3. Quantitative Echocardiographic Measures

    Time frame: Measured at the second visit (V2) at 2 weeks.

    Agreement between the two echocardiography techniques will be assessed using the intraclass correlation coefficient (ICC), paired Student's t-test, and Bland-Altman plots for the following measures:

    Diastolic function - mitral Doppler inflow/outflow (I/O) ratio and tissue Doppler I/O ratio; Aortic flow - measured from subaortic velocity-time integral (ITV); Systolic pulmonary arterial pressure - derived from tricuspid insufficiency using the Bernoulli formula; Right ventricular systolic function - assessed by TAPSE.

  4. Hypertrophic Cardiomyopathy Assessment

    Time frame: Measured at Visit 2 (V2), 2 weeks after baseline.

    Presence or absence of hypertrophic cardiomyopathy will be defined based on septal and posterior wall thickness and reported as number of participants with hypertrophic cardiomyopathy for each technique.

  5. Valvulopathy Assessment

    Time frame: Measured at V2 (2 weeks)

    Presence or absence of aortic or mitral stenosis and regurgitation will be reported as number of participants with valvulopathies for each technique.

  6. Systolic Pulmonary Arterial Pressure (PAP)

    Time frame: Measured at V2 (2 weeks)

    Systolic PAP will be measured from tricuspid regurgitation or estimated indirectly from systolic pulmonary ejection flow. Reported in mmHg.

  7. Left Ventricular Filling Pressure

    Time frame: Measured at V2 (2 weeks)

    Changes in left ventricular (LV) filling pressures will be assessed using the E/e' ratio (mitral Doppler flow / tissue Doppler flow at the mitral annulus).

  8. Duration of Echocardiography

    Time frame: Measured at the second visit (V2) at 2 weeks.

    Total duration of each echocardiography session will be recorded in minutes for both techniques.

  9. Patient Satisfaction

    Time frame: Measured at the second visit (V2) at 2 weeks.

    Patient satisfaction with the tele-echocardiography procedure will be assessed using an adapted TeleHealth Satisfaction Questionnaire (TSQ).

    Each item is scored on a 5-point Likert scale (1 = very dissatisfied, 5 = very satisfied), resulting in a total score range of 0 to 100 after standardization, where higher scores indicate greater satisfaction.

    All assessments will be conducted at the tele-echocardiography session by a blinded evaluator or self-reported by the patient.

Study contacts

Contact information is provided by the study sponsor or research team.

Valérie Hamony Soter

CONTACT

[email protected]

+590590934677

melanie petapermal, Master degree

CONTACT

[email protected]

+590590934667

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de la Guadeloupe

Other

Collaborators

  • GIRCI SOHO

Registry information

Acronym: TER de blueS

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 5, 2025
Registry last updated
Dec 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.